Blackstone and TPG are in the late stages of negotiations to acquire Hologic, a medical device and diagnostics company focused on women’s health, according to Bloomberg.
The investment managers proposed an offer of more than $75 per share, the news outlet reported, which represents a roughly 4.3% premium to the company’s share price as of market close on Monday.
A deal on these terms would value the New York-listed business at around $17 billion, including debt, making it one of the largest PE-backed acquisitions to take place in 2025.
TPG and Blackstone made an initial $16.7 billion non-binding offer in May that was subsequently rejected, The Financial Times reported.
The largest M&A deal in the healthcare space so far this year is Johnson & Johnson’s $14.6 billion take-private of Intracellular Therapies, which develops drugs to combat conditions such as depression and schizophrenia.
Medical devices and supplies businesses accounted for 1.9% of PE deals by value in the year to Sept. 30, equivalent to $12.7 billion in deal value, according to PitchBook’s latest US PE Breakdown.
Founded in 1985, Hologic produces imaging systems and surgical devices aimed at treating breast cancer.
The Marlborough, Mass., business saw its operating profit peak at $2.48 billion in full-year 2021 as it carved out a business producing molecular tests for COVID-19.
Its profitability has been on a steady decline since then, hitting $931 million in full-year 2024.
Hologic went public in 1990 and has since raised $21.5 billion in debt and equity financing.
Learn about our editorial standards.